deCODE genetics, Inc. (deCODE) is a bio-pharmaceutical company developing and marketing products for the treatment, diagnosis, and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in therapeutic areas, and applies its discoveries in human genetics to bring to market deoxyribonucleic acid (DNA)-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. In November 2009, the Company announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware.

Since its inception in 1982, AIM International, Inc. has made and marketed food concentrates and nutritional supplements through direct sales and through "members" who sell and distribute in a multilevel marketing arrangement. On the company's 25th anniversary, CEO Dennis Itami added a personal-care line to the product mix. The company's roster also includes a line of supplements for athletes. AIM International (dba The AIM Companies) has offices in Australia, Canada, New Zealand, South Africa, and the UK. Lead products include AIM BarleyLife and AIMega.

CEO Marc Coucke co-founded Omega Pharma NV company in 1987. Omega Pharma's first product was generic shampoo, which it sold to pharmacies. Omega Pharma NV is a Belgium-based provider of healthcare products and services for the pharmacies and other medical sectors. The Company specializes in the development, marketing and sales of health and personal care products, which can be obtained by the end-consumer without medical prescription (over the counter or OTC products). Omega Pharma NV consists of five business units, and is engaged in the provision of consumer-oriented medicines and healthcare products. It is composed of Omega Pharma Belgium, Omega Pharma France, Omega Pharma Northern Europe, Omega Pharma Southern Europe and Omega Pharma Rest of the World. As of December 31, 2008, the Company operated in over 30 countries, including most of the European countries, as well as Australia, New Zealand and Argentina.

Merck was founded in 1668 as a pharmacy and is the oldest pharmaceutical business in the world. The Merck family owns about 70% of the company. Merck is leaving its mark on the global pharmaceutical market. Through a network of nearly 200 companies in over 60 countries, the Merck develops, makes, and sells pharmaceutical and chemical products for global consumption. Name-brand prescription drugs include treatments for cardiovascular disease, cancers, infertility, and neurological disorders; the company also makes over-the-counter pharmaceuticals. Aside from drugs, the firm makes specialty chemicals, including laboratory reagents and cosmetic ingredients, as well as liquid crystals for televisions.

StemCells, Inc. company was founded in 1988 and is based in Palo Alto, California. StemCells, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders. In December 2008, the Company received authorization from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. In April 2009, StemCells, Inc. completed the acquisition of substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.

Peplin, Inc. company is developing drugs aimed at treating potentially cancerous skin conditions. Its lead drug candidate, a topical gel, is intended to serve as a less-costly alternative to surgical treatments for a common pre-cancerous skin condition known as actinic keratosis (AK). Derived from a plant known as petty spurge or radium weed, the product will be used to treat AK (characterized by rough patches of skin resulting from excessive exposure to sunlight) before it develops into skin cancer. Peplin was acquired by pharmaceutical giant LEO Pharma in late 2009 for $285 million.

Prometheus company markets several drugs that treat gastrointestinal disorders, such as irritable bowel syndrome and ulcerative colitis. Its Entocort, which it co-promotes with AstraZeneca, is a steroid that reduces the bowel inflammation associated with Crohn's disease. Prometheus Laboratories markets its products mainly to US gastroenterologists. It also pairs its drug offerings with a diagnostic testing service that helps doctors differentiate between various gastrointestinal diseases and prescribe the right Prometheus remedy; it runs all of its tests at its San Diego lab facility. Prometheus company plans to conduct an IPO.

AVAX Technologies company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate M-Vax is intended as a post-surgical treatment for late-stage melanoma, but the company is also developing vaccine candidates to fight ovarian cancer (O-Vax) and non-small cell lung cancer (L-Vax). The company also offers contract manufacturing services to other biotech and pharmaceutical companies.

Teva Pharmaceutical Industries Limited company was founded in 1901 and is headquartered in Petach Tikva, Israel. Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories. The Company has a pharmaceutical business, whose principal products are Copaxone for multiple sclerosis and Azilect for Parkinson’s disease and respiratory products. Teva’s active pharmaceutical ingredient business provides vertical integration to Teva’s own pharmaceutical production and sells to third party manufacturers. The Company’s global operations are conducted in North America, Europe, Latin America, Asia and Israel. Teva has operations in more than 60 countries, as well as 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 20 generic research and development centers operating mostly within certain manufacturing sites and 20 API manufacturing sites around the world. In January 2009, Phibro Animal Health Corporation completed the acquisition of the Abic Animal Health business from the Company.

ARIUS Research Inc. company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG. ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company’s product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.